drugset
Drugs / AIC
last change Apr 2010 re-read 3 minutes ago

AIC

Oligonucleotide (other)

Developed for
seasonal allergic rhinitis
Investigated by
Dynavax Technologies Corporation

Trials 1

today NCT00537355 · Ph 2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00537355 Sep 2007 → Mar 2008 seasonal allergic rhinitis Dynavax Technologies Corporation Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as AIC “Amb a 1-immunostimulatory oligodeoxynucleotide conjugate (AIC)-treated (n=17)” PMID 20412135 ↗ Apr 2010
Modality Oligonucleotide (other) “Amb a 1-immunostimulatory oligodeoxynucleotide conjugate (AIC)-treated (n=17)” PMID 20412135 ↗ Apr 2010
Route Subcutaneous “6 weekly subcutaneous injections” NCT00537355 ↗